Flag of the European Union EU Clinical Trials Register Help

Clinical trials for "prostate cancer" OR "breast cancer"

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    596 result(s) found for: "prostate cancer" OR "breast cancer". Displaying page 6 of 30.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    EudraCT Number: 2005-001271-35 Sponsor Protocol Number: ASL603LIOM03 CAGE Start Date*: 2005-07-18
    Sponsor Name:AZIENDA USL 6 LIVORNO ZONA LIVORNESE
    Full Title: ASSOCIATION OF CAPECITABINA And GEMCITABIN In METASTATIC MAMMARY CARCINOMA CLINICAL STUDY of Dose-finding and Activity Of the ASSOCIATION PHASE I-II
    Medical condition: Capecitabina and gemcitabina are singularly active drugs in the dealt breast cancer and with various profile of toxicity;they exist give to you preclinical of synergy in vitro between two drugs;the...
    Disease: Version SOC Term Classification Code Term Level
    6.1 10055113 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002839-10 Sponsor Protocol Number: GERICO 04/0406 Start Date*: 2006-08-03
    Sponsor Name:Fédération Nationale des Centres de Lutte Contre le Cancer
    Full Title: Phase II trial assessing the impact on instrumental and daily living autonomy of a chemotherapy regimen with bi-weekly docetaxel in the treatment of metastatic breast cancer in patients over the ag...
    Medical condition: HR+ or HR- metastatic adenocarcinoma of the breast with a measurable target (RECIST criteria) in patients aged 70 or over
    Disease: Version SOC Term Classification Code Term Level
    V5 10027475 LLT
    Population Age: Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-002104-40 Sponsor Protocol Number: CNIO-CP-2019-01 Start Date*: 2019-11-12
    Sponsor Name:Centro Nacional de Investigaciones Oncológicas (CNIO)
    Full Title: A phase II, open-label, biomarker-guided study of Carboplatin efficacy in pretreated metastatic castration-resistant Prostate Cancer (mCRPC)-BioChiP
    Medical condition: metastatic prostate cancer castration resistant
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003096-20 Sponsor Protocol Number: MedOPP234 Start Date*: 2020-05-29
    Sponsor Name:Medica Scientia Innovation Research S.L. (MEDSIR)
    Full Title: A randomized phase II trial to evaluate the antitumor activity of Enzalutamide and Talazoparib (PF-06944076) for the treatment of metastatic hormone-naïve prostate cancer
    Medical condition: Metastatic hormone–naïve prostate cancer (mHNPC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036920 Prostate cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-005019-18 Sponsor Protocol Number: ELPIS Start Date*: 2020-08-06
    Sponsor Name:Fundació Clínic per a la Recerca Biomèdica
    Full Title: Omission of surgery and sentinel lymph node dissection in clinically low-risk HER2positive breast cancer with high HER2 addiction and a complete response following standard anti- HER2-based neoadju...
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2006-000436-27 Sponsor Protocol Number: BR3031 Start Date*: 2007-02-16
    Sponsor Name:University of Birmingham [...]
    1. University of Birmingham
    2. University Hospital Birmingham NHS Foundation Trust
    Full Title: Neoadjuvant trial of pre-operative exemestane or letrozole +/-celecoxib in the treatment of ER positive postmenopausal early breast cancer.
    Medical condition: Postmenopausal early breast cancer
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2009-017596-26 Sponsor Protocol Number: RESTORE Start Date*: 2010-03-10
    Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST
    Full Title: Terapia di II linea con Docetaxel + Lanreotide in pazienti con carcinoma prostatico metastatico ormonorefrattario e in progressione in corso di chemioterapia di I linea con Docetaxel. Studio di fas...
    Medical condition: METASTATIC HORMONREFRACTORY PROSTATE CARCINOMA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007453 LLT
    Population Age: Elderly Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004045-33 Sponsor Protocol Number: NL70759.100.19 Start Date*: 2020-09-07
    Sponsor Name:Catharina Hospital Eindhoven
    Full Title: PredicTive value of FluoR-18 PSMA-1007 PET/CT and anti-3-[18F] FACBC PET/CT before PLND for lymph nodE staging in primary pRostate cancer
    Medical condition: Prostate cancer (PCa) is the most common malignancy amongst men in Western countries. In order to select the most suitable treatment for patients diagnosed with PCa, it is important to stage accu...
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003154-12 Sponsor Protocol Number: FSK2011-01 Start Date*: 2011-11-16
    Sponsor Name:Privatärztliche urologische Partnerschaft GbR, EuromedClinic
    Full Title: Circulating Tumor Cells in Patients with Castration Resistant Metastatic Prostate Cancer Undergoing Zoledronate Therapy
    Medical condition: hormone refractory metastatic prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005116-28 Sponsor Protocol Number: 38495 Start Date*: 2012-09-10
    Sponsor Name:
    Full Title: A phase I/II trial of Cabazitaxel +/- Rhenium-188 HEDP in patients with metastatic castration resistant prostate cancer who progressed on or after a docetaxel containing treatment. The ReCab trial
    Medical condition: Metastatic prostate cancer/bone metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004991-16 Sponsor Protocol Number: tba Start Date*: 2022-09-28
    Sponsor Name:
    Full Title: 177Lu-PSMA RADIOLIGAND THERAPY IN PATIENTS WITH LYMPH NODE METASTATIC HORMONE-SENSITIVE PROSTATE CANCER UNDERGOING ROBOT-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY AND EXTENDED PELVIC LYMPH NODE D...
    Medical condition: prostate cancer, eligible for radical prostatectomy and extended pelvic lymph node dissection, with 1-3 pelvic nodal metastases on preoperative PSMA PET
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002914-10 Sponsor Protocol Number: 66856 Start Date*: 2019-09-16
    Sponsor Name:Erasmus MC Cancer Institute
    Full Title: FUnctional selection of advanced breast cancer patients for Talazoparib treatment Using the REpair Capacity (RECAP) test: The FUTURE trial
    Medical condition: Advanced or metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001022-17 Sponsor Protocol Number: 170304 Start Date*: 2017-05-08
    Sponsor Name:Breastcentre, Capio St Gorans Hospital
    Full Title: Vitamin D supplementation to breast cancer patients with adjuvant endocrine treatment – An observational clinical study where the patient is its own control.
    Medical condition: Breast cancer survivors on adjuvant treatment with an aromatase inhibitor having joint pain
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-001030-33 Sponsor Protocol Number: MRCPR09 Start Date*: 2005-11-23
    Sponsor Name:University College London
    Full Title: PATCH Prostate Adenocarcinoma: TransCutaneous Hormones A randomised-controlled trial of transcutaneous oestrogen patches versus LHRH agonists in prostate cancer.
    Medical condition: Newly diagnosed or relapsing patients with locally advanced or metastatic prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-002531-83 Sponsor Protocol Number: IC2007-01 Start Date*: 2007-10-10
    Sponsor Name:Institut Curie
    Full Title: Etude de phase 2 randomisée comparant une irradiation encéphalique associée au témozolomide à une irradiation seule chez des patientes présentant des métastases cérébrales d'un cancer du sein.
    Medical condition: Patientes présentant des métastases cérébrales d'un cancer du sein, non opérables ou refus de chirurgie. Age > 18 ans. OMS ≤ 2. Pas d’antécédent d’irradiation encéphalique. Le délai entre la fi...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10055113 Breast cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000987-18 Sponsor Protocol Number: TRAIN Start Date*: 2008-07-10
    Sponsor Name:Netherlands Cancer Institute
    Full Title: Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study
    Medical condition: HER2 positive breat cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001226-25 Sponsor Protocol Number: HD-TNBC-TRIAL Start Date*: 2015-04-20
    Sponsor Name:ISTITUTI OSPITALIERI DI CREMONA
    Full Title: A phase II randomized, open-label neo-adjuvant study of standard chemotherapy regimen compared to high dose chemotherapy regimen with autologous stem cell transplantation in patients with triple ne...
    Medical condition: Triple Negative Breast Cancer patients with breast tumor >2,5 cm
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-007027-40 Sponsor Protocol Number: 0205-1isni07 / 001.112 Start Date*: 2008-03-07
    Sponsor Name:Centre Georges-François Leclerc
    Full Title: A Multicenter open-label, phase I/II dose escalation study of oral lapatinib in combination with docetaxel in patients with HER2 positive advanced or metastatic breast cancer
    Medical condition: HER 2 positive advanced or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-016932-11 Sponsor Protocol Number: 15051982 Start Date*: 2010-03-08
    Sponsor Name:BOOG Study Center B.V
    Full Title: Phase III randomized trial with neoadjuvant chemotherapy (TAC) with or without zoledronic acid for patients with HER2-negative breast cancer.
    Medical condition: Patients with locally advanced or large resectable HER2-negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10006195 Breast cancer NOS stage II LLT
    12.1 10006196 Breast cancer NOS stage III LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-003323-17 Sponsor Protocol Number: IMP321-P016 Start Date*: 2023-03-24
    Sponsor Name:Immutep S.A.S.
    Full Title: AIPAC-003: A randomized, double-blind, placebo-controlled Phase 3 trial testing eftilagimod alpha (soluble LAG-3) in HER2-neg/low metastatic breast cancer patients receiving paclitaxel, following a...
    Medical condition: HER2-neg/low metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006202 Breast cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Apr 05 03:14:52 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA